Pharmacare held a scientific lecture at the Grand Park Hotel in the city of Ramallah today 14/1/2019 to launch its newest addition to its family of antidiabetic drugs.
It is the first Palestinian manufactured antidiabetic drug containing Sitagliptin and Metformin. Physicians commonly prescribe a combination of Sitagliptin and Metformin to control type 2 diabetes; this medication combines both in one convenient package, at a price offering more than 35% in savings over the alternative from the drug originators.
SitaGlu-Met® provides a comprehensive treatment option for people with type 2 diabetes and may in some instances delay insulin dependency, and improve quality of life. Pharmacare strives to deliver International standards quality products at affordable prices.
SitaGlu-Met® will be available in three doses of Sitagliptin and Metformin respectively, and they are as follows: [50mg / 500mg], [50mg / 850mg], and [50mg / 1000mg].
At the Grand Park Hotel, physicians from various specialties namely Internists, Cardiologists, and Endocrinologists participated in the scientific discussion, which took place at 7:00 pm.
The discussion was followed by a brief presentation by Mr. Rami Majrouh, Brand Manager at Pharmacare, in which he discussed some of Pharmacare’s history, mission, profile, achievements, certifications, international markets, business model, product portfolio, Pharmacare Premium, Pharmacare Quality policy, and Pharmacare’s 2020 strategy. The presentation was followed by a dinner for the participants.
The lecturer was Dr. Raed Al Alami, Consultant Endocrinologist and Diabetologist, member of the French and Palestinian Boards, delivered a lecture entitled “AACE/ACE Comprehensive Type 2 Diabetes Management Algorithm”.
The lecture discussed an algorithm for the comprehensive management of persons with type 2 diabetes (T2D) was developed to provide clinicians with a practical guide that considers the whole patient, his or her spectrum of risks and complications, and evidence-based approaches to treatment.
This algorithm supplements the American Association of Clinical Endocrinologists (AACE) and American College of Endocrinology (ACE) 2015 Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan (2) and is organized into discrete sections that address the following topics: the founding principles of the algorithm, lifestyle therapy, obesity, prediabetes, glucose control with non insulin antihyperglycemic agents and insulin, and management of hypertension and dyslipidemia. In the accompanying algorithm, a chart summarizing the attributes of each antihyperglycemic class and the principles of the algorithm appear at the end.